Jethro Holter
Algemeen Directeur bij ArcticZymes AS
Vermogen: 188 421 $ op 30-04-2024
Profiel
Jethro Holter is currently the Chief Executive Officer at Biotec BetaGlucans AS and the Managing Director at ArcticZymes AS.
Previously, he was the Chief Executive Officer at ArcticZymes Technologies ASA from 2019 to 2023 and held a Director-Research & Development position at Mole Genetics AS.
He earned a doctorate degree from the University of Cardiff.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2023 | 80 564 ( 0.16% ) | 188 421 $ | 30-04-2024 |
Actieve functies van Jethro Holter
| Bedrijven | Functie | Begin |
|---|---|---|
ArcticZymes AS
 ArcticZymes AS Medical SpecialtiesHealth Technology Part of ArcticZymes Technologies ASA, ArcticZymes AS is a Norwegian company that manufactures diagnostic substances. The company is based in Tromsø, Norway. Jethro Holter has been the CEO of the company since 2015. | Algemeen Directeur | 01-01-2015 |
Biotec BetaGlucans AS
 Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Algemeen Directeur | - |
Eerdere bekende functies van Jethro Holter
| Bedrijven | Functie | Einde |
|---|---|---|
| ARCTICZYMES TECHNOLOGIES ASA | Algemeen Directeur | 18-09-2023 |
Mole Genetics AS
 Mole Genetics AS BiotechnologyHealth Technology Mole Genetics AS manufactures and sells instruments & pre-filled reagent cartridges for genetic research. The firm product GeneMole is used for automation of DNA and RNA extraction system and MoleStrips is used for prefilled disposable reagent strips. The company was founded by Ole Jesper Dahlberg, Frank Larsen, Arne Deggerdal, and Tone Yrvum in June 2005 and is headquartered in Lysaker, Norway. | Corporate Officer/Principal | - |
Opleiding van Jethro Holter
| University of Cardiff | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Mole Genetics AS
Mole Genetics AS BiotechnologyHealth Technology Mole Genetics AS manufactures and sells instruments & pre-filled reagent cartridges for genetic research. The firm product GeneMole is used for automation of DNA and RNA extraction system and MoleStrips is used for prefilled disposable reagent strips. The company was founded by Ole Jesper Dahlberg, Frank Larsen, Arne Deggerdal, and Tone Yrvum in June 2005 and is headquartered in Lysaker, Norway. | Health Technology |
ArcticZymes AS
ArcticZymes AS Medical SpecialtiesHealth Technology Part of ArcticZymes Technologies ASA, ArcticZymes AS is a Norwegian company that manufactures diagnostic substances. The company is based in Tromsø, Norway. Jethro Holter has been the CEO of the company since 2015. | Health Technology |
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Health Technology |